Apyx Medical (NASDAQ:APYX) Shares Down 1.9% – Should You Sell?

Apyx Medical Corporation (NASDAQ:APYX) was down 1.9% on Monday . The company traded as low as $4.55 and last traded at $4.60. Approximately 134,598 shares traded hands during trading, a decline of 14% from the average daily volume of 156,646 shares. The stock had previously closed at $4.69.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on APYX shares. Wall Street Zen lowered Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research note on Friday, March 27th. Finally, Craig Hallum raised their price objective on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Apyx Medical Stock Performance

The stock has a market capitalization of $176.27 million, a P/E ratio of -19.14 and a beta of 1.39. The company’s 50-day moving average is $3.98 and its two-hundred day moving average is $3.83. The company has a current ratio of 5.80, a quick ratio of 4.79 and a debt-to-equity ratio of 2.68.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.06. The firm had revenue of $12.49 million for the quarter, compared to the consensus estimate of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC acquired a new stake in shares of Apyx Medical in the first quarter valued at $255,000. Renaissance Technologies LLC lifted its holdings in shares of Apyx Medical by 37.2% during the first quarter. Renaissance Technologies LLC now owns 302,395 shares of the company’s stock valued at $1,116,000 after purchasing an additional 82,000 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after purchasing an additional 448,174 shares during the last quarter. Nwam LLC purchased a new stake in shares of Apyx Medical during the first quarter valued at $47,000. Finally, Hillsdale Investment Management Inc. lifted its holdings in shares of Apyx Medical by 84.4% during the first quarter. Hillsdale Investment Management Inc. now owns 174,300 shares of the company’s stock valued at $643,000 after purchasing an additional 79,800 shares during the last quarter. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.